Open AccessLong non‐coding RNA PVT1: Emerging biomarker in digestive system cancer
Author(s) -
Zhou DanDan,
Liu Xiufen,
Lu Chengwei,
Pant Om Prakash,
Liu Xiaodong
Publication year - 2017
Publication title -
cell proliferation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.647
H-Index - 74
eISSN - 1365-2184
pISSN - 0960-7722
DOI - 10.1111/cpr.12398
Subject(s) - cancer , biomarker , cancer research , metastasis , pvt1 , long non coding rna , colorectal cancer , biology , pancreatic cancer , medicine , oncology , rna , gene , biochemistry
The digestive system cancers are leading cause of cancer‐related death worldwide, and have high risks of morbidity and mortality. More and more long non‐coding RNA s (lnc RNA s) have been studied to be abnormally expressed in cancers and play a key role in the process of digestive system tumour progression. Plasmacytoma variant translocation 1 ( PVT 1) seems fairly novel. Since 1984, PVT 1 was identified to be an activator of MYC in mice. Its role in human tumour initiation and progression has long been a subject of interest. The expression of PVT 1 is elevated in digestive system cancers and correlates with poor prognosis. In this review, we illustrate the various functions of PVT 1 during the different stages in the complex process of digestive system tumours (including oesophageal cancer, gastric cancer, colorectal cancer, hepatocellular carcinoma and pancreatic cancer). The growing evidence shows the involvement of PVT 1 in both proliferation and differentiation process in addition to its involvement in epithelial to mesenchymal transition ( EMT ). These findings lead us to conclude that PVT 1 promotes proliferation, survival, invasion, metastasis and drug resistance in digestive system cancer cells. We will also discuss PVT 1's potential in diagnosis and treatment target of digestive system cancer. There was a great probability PVT 1 could be a novel biomarker in screening tumours, prognosis biomarkers and future targeted therapy to improve the survival rate in cancer patients.